<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan's syndrome</z:e> is an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> condition with an estimated prevalence of one in 10,000 to 20,000 individuals </plain></SENT>
<SENT sid="1" pm="."><plain>This rare hereditary <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disorder</z:e> affects many parts of the body </plain></SENT>
<SENT sid="2" pm="."><plain>The diagnosis of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan's syndrome</z:e> is established in accordance with a review of the diagnostic criteria, known as the Ghent nosology, through a comprehensive assessment largely based on a combination of major and minor clinical manifestations in various organ systems and the family history </plain></SENT>
<SENT sid="3" pm="."><plain>Aortic root dilation and <z:hpo ids='HP_0001634'>mitral valve prolapse</z:hpo> are the main presentations among the <z:hpo ids='HP_0002564'>cardiovascular malformations</z:hpo> of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan's syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The pathogenesis of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan's syndrome</z:e> has not been fully elucidated </plain></SENT>
<SENT sid="5" pm="."><plain>However, fibrillin-1 gene mutations are believed to exert a dominant negative effect </plain></SENT>
<SENT sid="6" pm="."><plain>Therefore, <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan's syndrome</z:e> is termed a fibrillinopathy, along with other <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disorders</z:e> with subtle differences in clinical manifestations </plain></SENT>
<SENT sid="7" pm="."><plain>The treatment may include prophylactic β-blockers and <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi>-receptor blockers in order to slow down the <z:hpo ids='HP_0005111'>dilation of the ascending aorta</z:hpo>, and prophylactic aortic surgery </plain></SENT>
<SENT sid="8" pm="."><plain>Importantly, β-blocker therapy may reduce TGF-β activation, which has been recognized as a contributory factor in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan's syndrome</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The present article aims to provide an overview of this rare <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">hereditary disorder</z:e> </plain></SENT>
</text></document>